oral semaglutide 50 mg oasis 1 nejm 2023 obesity Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential Study reveals oral Semaglutide 50

This advanced formulation is particularly beneficial for individuals at increased risk of deficiency, including the elderly, vegetarians, vegans, and those with GI conditions that hinder B12 absorption, such as pernicious anemia, celiac disease, Crohns disease, and irritable bowel syndrome (IBS), among others

When you feel full sooner, you consume fewer calories and begin to lose weight

& Hood, M

FDA approves once-daily oral Wegovy (semaglutide) tablets 25 mg for weight loss and MACE risk reduction in adults with overweight/obesity (OASIS 4: ~17% mean weight loss at 64 weeks vs ~3% with placebo) - Vera Health News

A useful overview of that link is in microbiota-immune, which explains how microbes steer immune behavior